, , -
Many of the neuroprotective, neurodegenerative, psychiatric, and addiction-related applications discussed remain investigational, and no GLP-1 receptor agonist is currently approved by regulatory authorities for the treatment or prevention of Alzheimers disease, Parkinsons disease, depression, substance use disorders, or other neurological indications unless specifically stated otherwise
PMC 7507632
Started Retatrutide in August at 194, dropped pretty steadily until mid-October, then nothing
Many of our patients love discovering the benefits of semaglutide, including weight loss, a once-weekly subcutaneous injection, clinical studies, which provides a non-surgical option for weight loss compared to more invasive procedures like bariatric surgery
Maintaining good hygiene can help prevent this